

FOR PUBLIC RELEASE

NZX Limited
Wellington

Wednesday 19 January, 2022

Presentation Slides and Commentary Available for Rua Bioscience Ltd Special Shareholders' Meeting

The attached 'Presentation Slides' and 'Chairman and CEO Commentary' will be presented at the Rua Bioscience Special Shareholders' Meeting, held to consider the proposed acquisition of Zalm Therapeutics.

The meeting is online, held at 12.00pm (New Zealand time) on 19 January 2022 and hosted on Computershare Investor Services Limited's (**Computershare's**) meeting platform <https://meetnow.global/nz>.

ENDS

For more information, please visit www.ruabio.com or contact:

Media

Kerry Donovan
Communications Manager
+64 (21) 128 7689
kerry.donovan@ruabio.com

Investors

Hamish White
Chief Financial Officer
+64 (21) 050 5795
Hamish.white@ruabio.com

About Rua Bioscience

Rua Bioscience is a New Zealand pharmaceutical company aiming to produce cannabinoid derived medicines for both export and local markets. Rua has been an early mover in the sector and was the first private company in New Zealand to receive a licence to cultivate Cannabis for research purposes. Founded in 2017 in Ruatorea as a subsidiary of charitable company Hikurangi Enterprises Limited, Rua is underpinned by its mission to heal the people and heal the land. It is committed to New Zealand's Te Tairāwhiti (East Coast) region and its local community. The Company has completed facilities for cultivation and manufacturing and received GMP certification. www.ruabio.com